As of 2026-03-21, the Relative Valuation of Madrigal Pharmaceuticals Inc (MDGL) is (253.85) USD. This relative valuation is based on P/E multiples. With the latest stock price at 441.16 USD, the upside of Madrigal Pharmaceuticals Inc based on Relative Valuation is -157.5%.
The range of the Relative Valuation is (223.19) - (270.44) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.8x - 23.4x | 20.0x |
| Forward P/E multiples | 16.5x - 21.5x | 20.4x |
| Fair Price | (223.19) - (270.44) | (253.85) |
| Upside | -150.6% - -161.3% | -157.5% |
| Date | P/E |
| 2026-03-13 | -35.40 |
| 2026-03-12 | -34.91 |
| 2026-03-11 | -34.34 |
| 2026-03-10 | -34.44 |
| 2026-03-09 | -34.47 |
| 2026-03-06 | -34.44 |
| 2026-03-05 | -34.96 |
| 2026-03-04 | -34.60 |
| 2026-03-03 | -33.89 |
| 2026-03-02 | -34.66 |
| 2026-02-27 | -34.38 |
| 2026-02-26 | -35.48 |
| 2026-02-25 | -34.62 |
| 2026-02-24 | -35.01 |
| 2026-02-23 | -34.84 |
| 2026-02-20 | -34.62 |
| 2026-02-19 | -34.76 |
| 2026-02-18 | -39.11 |
| 2026-02-17 | -38.78 |
| 2026-02-13 | -36.98 |
| 2026-02-12 | -37.70 |
| 2026-02-11 | -38.28 |
| 2026-02-10 | -38.10 |
| 2026-02-09 | -38.85 |
| 2026-02-06 | -38.00 |
| 2026-02-05 | -36.88 |
| 2026-02-04 | -38.09 |
| 2026-02-03 | -38.39 |
| 2026-02-02 | -38.97 |
| 2026-01-30 | -38.94 |
| 2026-01-29 | -39.36 |
| 2026-01-28 | -39.51 |
| 2026-01-27 | -39.82 |
| 2026-01-26 | -39.72 |
| 2026-01-23 | -38.23 |
| 2026-01-22 | -39.63 |
| 2026-01-21 | -39.55 |
| 2026-01-20 | -40.18 |
| 2026-01-16 | -39.92 |
| 2026-01-15 | -39.46 |
| 2026-01-14 | -40.20 |
| 2026-01-13 | -39.30 |
| 2026-01-12 | -40.63 |
| 2026-01-09 | -40.91 |
| 2026-01-08 | -44.26 |
| 2026-01-07 | -44.65 |
| 2026-01-06 | -44.40 |
| 2026-01-05 | -46.82 |
| 2026-01-02 | -47.26 |
| 2025-12-31 | -46.34 |